Study to evaluate Pegcetacoplan in patients with TA-TMA after hematopoietic stem cell transplantatio
- Conditions
- Transplant-associated Thrombotic Microangiopathy (TA TMA)MedDRA version: 20.0Level: PTClassification code: 10043645Term: Thrombotic microangiopathy Class: 100000004851Therapeutic area: Diseases [C] - Hemic and Lymphatic Diseases [C15]
- Registration Number
- CTIS2023-510443-37-00
- Lead Sponsor
- Swedish Orphan Biovitrum AB (publ)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 12
Male and female patients aged = 18 years at the time of informed consent form (ICF) signature., Received allogeneic HSCT from a related or unrelated, human leukocyte antigen-matched or mismatched donor. Patients having received any of the following stem cell sources are eligible: granulocyte colony stimulating factor mobilized peripheral blood stem cells, bone marrow, umbilical cord blood., Diagnosis of TA-TMA established as per the laboratory markers below, indicating TMA: a. De novo or progressing thrombocytopenia (platelet count < 50 x 109 /L or > 50 % decrease in platelet count from the highest value achieved after transplantation). AND b. Elevated LDH (> 1.5 x ULN). AND at least 2 additional laboratory/clinical criteria among the following: c. Presence of schistocytes on the peripheral blood smear (= 2 per hpf) or histologic evidence of microangiopathy in any biopsied organ. OR d. De novo anemia (hemoglobin < LLN or anemia requiring PRBC transfusion support as per local institutional standard). OR e. Proteinuria (random urinalysis protein concentration = 30 mg/dL). OR f. Elevated plasma concentration of sC5b-9 above ULN. OR g. Arterial hypertension, defined by systolic blood pressure (BP) = 140 mmHg and/or diastolic BP = 90 mmHg., Have a diagnosis of TA-TMA that persists despite initial management of any triggering condition., Have rUPCR = 1 mg/mg, Women of childbearing potential, defined as any women who have experienced menarche and who are NOT permanently sterile or postmenopausal, must have a negative serum pregnancy test at screening and agree to use protocol-defined methods of contraception for the duration of the study and 8 weeks after their last IMP dose. Note: Postmenopausal is defined as having had 12 consecutive months with no menses without an alternative medical cause., Men must agree to the following for the duration of the study and 8 weeks after their last dose of IMP: a. Avoid fathering a child. b. Use protocol-defined methods of contraception. c. Refrain from donating sperm., Patient and/or legally authorized representative must be capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the ICF.
Positive direct Coombs test., Previously or currently treated with a complement inhibitor (approved or investigational)., Pregnancy or breastfeeding, Positive human immunodeficiency virus antibody at screening or documented in pre-HSCT medical record., Hepatitis C virus detectable by polymerase chain reaction at screening or documented in pre-HSCT medical record., Chronic inactive hepatitis B virus with viral loads > 1000 IU/mL (> 5000 copies/mL) at screening or documented in pre-HSCT medical record. Eligible patients who are chronic active carriers (= 1000 IU/mL) must receive prophylactic antiviral treatment (e.g., entecavir, tenofovir, lamivudine) according to local country guidelines, Known or suspected hereditary fructose intolerance., Hypersensitivity to pegcetacoplan or any of its excipients., Inability to cooperate with study procedures or any condition that, in the opinion of the investigator, could increase the patient’s risk by participating in the study or confound the outcome of the study., Known familial or acquired ADAMTS13 deficiency., Known Shiga toxin-related hemolytic uremic syndrome., Known bone marrow or graft failure., Diagnosis of disseminated intravascular coagulation., Diagnosis of veno-occlusive disease (VOD)., Active GI bleeding (hematemesis or hematochezia) at baseline, Body weight < 30 kg and > 100 kg., Uncontrolled systemic bacterial or fungal infection, presence or suspicion of sepsis.
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Main Objective: To evaluate the pharmacokinetics (PK), safety and tolerability of pegcetacoplan in patients with TA-TMA.;Secondary Objective: To evaluate the PD of pegcetacoplan in patients with TA-TMA., To evaluate the efficacy of pegcetacoplan in patients with TA-TMA;Primary end point(s): Pegcetacoplan PK parameters: AUC0-tau, Cmax, Tmax and Ctrough.
- Secondary Outcome Measures
Name Time Method